Acute Ischemic Stroke Treatment, Part 2: Treatment "Roles of Capillary Index Score, Revascularization and Time"

Firas Al-Ali, John J Elias, Danielle E Filipkowski, Firas Al-Ali, John J Elias, Danielle E Filipkowski

Abstract

Due to recent results from clinical intra-arterial treatment for acute ischemic stroke (IAT-AIS) trials such as the interventional management of stroke III, IAT-AIS and the merit of revascularization have been contested. Even though intra-arterial treatment (IAT) has been shown to improve revascularization rates, a corresponding increase in good outcomes has only recently been noted. Even though a significant percentage of patients achieve good revascularization in a timely manner, results do not translate into good clinical outcomes (GCOs). Based on a review of the literature, the authors suspect limited GCOs following timely and successful revascularization are due to poor patient selection that led to futile and possibly even harmful revascularization. The capillary index score (CIS) is a simple angiography-based scale that can potentially be used to improve patient selection to prevent revascularization being performed on patients who are unlikely to benefit from treatment. The CIS characterizes presence of capillary blush related to collateral flow as a marker of residual viable tissue, with absence of blush indicating the tissue is no longer viable due to ischemia. By only selecting patients with a favorable CIS for IAT, the rate of GCOs should consistently approach 80-90%. Current methods of patient selection are primarily dependent on time from ischemia. Time from cerebral ischemia to irreversible tissue damage seems to vary from patient to patient; so focusing on viable tissue based on the CIS rather than relying on an artificial time window seems to be a more appropriate approach to patient selection.

Keywords: acute ischemic stroke; capillary index score; intra-arterial treatment; revascularization; stroke outcome.

Figures

Figure 1
Figure 1
Depth of ischemia and time to irreversible cerebral damage: time to irreversible cerebral damage depends on the depth of ischemia, which depends on the collateral supply. Since different patients have different collaterals, the depth of ischemia will vary among patients, as will the time available for therapy to salvage the tissue (8). Adapted with permission from Jones et al., (8). Permission has been obtained from the American Association of Neurological Surgeons.
Figure 2
Figure 2
Logarithmic time curve: the infarction threshold distinguishing between reversible and irreversible ischemia as a function of rCBF and time from ictus. The vertical lines are an approximation and have not yet been validated (18). Reproduced with permission from Al-Ali et al. (18). Permission has been provided by Wolters Kluwer Health, Inc.
Figure 3
Figure 3
Proposed patient selection algorithm for AIS.

References

    1. Broderick J, Palesch Y, Demchuk A, Yeatts S, Khatri P, Hill M, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med (2013) 368(10):893–903.10.1056/NEJMoa1214300
    1. Ciccone A, Valvassori L, Ponzio M, Ballabio E, Gasparotti R, Sessa M, et al. Intra-arterial or intravenous thrombolysis for acute ischemic stroke? The SYNTHESIS pilot trial. J Neurointerv Surg (2009) 2(1):74–9.10.1136/jnis.2009.001388
    1. Rha J, Saver J. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke (2007) 38(3):967–73.10.1161/01.STR.0000258112.14918.24
    1. Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, et al. A randomized trial of intra-arterial treatment for acute ischemic stroke. N Engl J Med (2015) 372(1):11–20.10.1056/NEJMoa1411587
    1. Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med (2015) 372(11):1009–18.10.1056/NEJMoa1414792
    1. Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med (2015) 372(11):1019–30.10.1056/NEJMoa1414905
    1. Higashida R, Furlan A. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. Stroke (2003) 34(8):e109–37.10.1161/01.STR.0000082720.85129.0A
    1. Jones T, Morawetz R, Crowell R, Marcoux F, FitzGibbon S, DeGirolami U, et al. Thresholds of focal cerebral ischemia in awake monkeys. J Neurosurg (1981) 54(6):773–82.10.3171/jns.1981.54.6.0773
    1. del Zoppo G, Higashida R, Furlan A, Pessin M, Rowley H, Gent M. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke (1998) 29(1):4–11.10.1161/01.STR.29.1.4
    1. IMS Study Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the interventional management of stroke study. Stroke (2004) 35(4):904–11.10.1161/01.STR.0000121641.77121.98
    1. IMS II Trial Investigators. The interventional management of stroke (IMS) II study. Stroke (2007) 38(7):2127–35.10.1161/STROKEAHA.107.483131
    1. Saver J, Jahan R, Levy E, Jovin T, Baxter B, Nogueira R, et al. Solitaire flow restoration device versus the merci retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. Lancet (2012) 380(9849):1241–9.10.1016/S0140-6736(12)61384-1
    1. Nogueira R, Lutsep H, Gupta R, Jovin T, Albers G, Walker G, et al. Trevo versus merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. Lancet (2012) 380(9849):1231–40.10.1016/S0140-6736(12)61299-9
    1. Gratz P, Jung S, Schroth G, Gralla J, Mordasini P, Hsieh K, et al. Outcome of standard and high-risk patients with acute anterior circulation stroke after stent retriever thrombectomy. Stroke (2013) 45(1):152–8.10.1161/STROKEAHA.113.002591
    1. Penumbra Pivotal Stroke Trial Investigators. The penumbra pivotal stroke trial: safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. Stroke (2009) 40(8):2761–8.10.1161/STROKEAHA.108.544957
    1. Tarr R, Hsu D, Kulcsar Z, Bonvin C, Rufenacht D, Alfke K, et al. The POST trial: initial post-market experience of the penumbra system: revascularization of large vessel occlusion in acute ischemic stroke in the United States and Europe. J Neurointerv Surg (2010) 2(4):341–4.10.1136/jnis.2010.002600
    1. Al-Ali F, Jefferson A, Barrow T, Cree T, Louis S, Luke K, et al. The capillary index score: rethinking the acute ischemic stroke treatment algorithm. Results from the Borgess Medical Center Acute Ischemic Stroke Registry. J Neurointerv Surg (2012) 5(2):139–43.10.1136/neurintsurg-2011-010146
    1. Al-Ali F, Tomsick T, Connors J, Gebel J, Elias J, Markarian G, et al. Capillary index score in the interventional management of stroke trials I and II. Stroke (2014) 45(7):1999–2003.10.1161/STROKEAHA.114.005304
    1. Tomsick T, Broderick J, Carrozella J, Khatri P, Hill M, Palesch Y, et al. Revascularization results in the interventional management of stroke II trial. Am J Neuroradiol (2008) 29(3):582–7.10.3174/ajnr.A0843
    1. Koh J, Lee S, Ryu C, Kim H. Safety and efficacy of mechanical thrombectomy with solitaire stent retrieval for acute ischemic stroke: a systematic review. Neurointervention (2012) 7(1):1.10.5469/neuroint.2012.7.1.1
    1. Khatri P, Abruzzo T, Yeatts S, Nichols C, Broderick J, Tomsick T. Good clinical outcome after ischemic stroke with successful revascularization is time-dependent. Neurology (2009) 73(13):1066–72.10.1212/WNL.0b013e3181b9c847
    1. Lees K, Bluhmki E, von Kummer R, Brott T, Toni D, Grotta J, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet (2010) 375(9727):1695–703.10.1016/S0140-6736(10)60491-6
    1. Saver J, Fonarow G, Smith E, Reeves M, Grau-Sepulveda M, Pan W, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA (2013) 309(23):2480.10.1001/jama.2013.6959
    1. Khatri P, Yeatts S, Mazighi M, Broderick J, Liebeskind D. Time to angiographic reperfusion is highly associated with good clinical outcome in the IMS III trial. Presentation Presented at the International Stroke Conference Honolulu, HI (2013).
    1. Khatri P, Yeatts S, Mazighi M, Broderick J, Liebeskind D, Demchuk A, et al. Time to angiographic reperfusion and clinical outcome after acute ischaemic stroke: an analysis of data from the interventional management of stroke (IMS III) phase 3 trial. Lancet Neurol (2014) 13(6):567–74.10.1016/S1474-4422(14)70066-3
    1. Qureshi A. Endovascular treatment of acute ischaemic stroke after 6 h of symptom onset: safe but is it efficacious? Eur J Neurol (2013) 20(6):863–4.10.1111/ene.12079
    1. Crowell R, Marcoux F, DeGirolami U. Variability and reversibility of focal cerebral ischemia in unanesthetized monkeys. Neurology (1981) 31(10):1295–1295.10.1212/WNL.31.10.1295
    1. Jovin T, Liebeskind D, Gupta R, Rymer M, Rai A, Zaidat O, et al. Imaging-based endovascular therapy for acute ischemic stroke due to proximal intracranial anterior circulation occlusion treated beyond 8 hours from time last seen well: retrospective multicenter analysis of 237 consecutive patients. Stroke (2011) 42(8):2206–11.10.1161/STROKEAHA.110.604223

Source: PubMed

3
Iratkozz fel